MaxCyte Statistics
Share Statistics
MaxCyte has 105.48M shares outstanding. The number of shares has increased by 1.3% in one year.
| Shares Outstanding | 105.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.37% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 97.35M |
| Failed to Deliver (FTD) Shares | 23.80K |
| FTD / Avg. Volume | 4.21% |
Short Selling Information
The latest short interest is 3.16M, so 3% of the outstanding shares have been sold short.
| Short Interest | 3.16M |
| Short % of Shares Out | 3% |
| Short % of Float | 3.25% |
| Short Ratio (days to cover) | 4.31 |
Valuation Ratios
The PE ratio is -12.8 and the forward PE ratio is -9.08.
| PE Ratio | -12.8 |
| Forward PE | -9.08 |
| PS Ratio | 11.76 |
| Forward PS | 8.1 |
| PB Ratio | 2.09 |
| P/FCF Ratio | -19.12 |
| PEG Ratio | n/a |
Enterprise Valuation
MaxCyte Inc. has an Enterprise Value (EV) of 457.60M.
| EV / Earnings | -12.07 |
| EV / Sales | 11.08 |
| EV / EBITDA | -10.37 |
| EV / EBIT | -9.47 |
| EV / FCF | -18.03 |
Financial Position
The company has a current ratio of 10.65, with a Debt / Equity ratio of 0.
| Current Ratio | 10.65 |
| Quick Ratio | 9.97 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.16% and return on capital (ROIC) is -19.25%.
| Return on Equity (ROE) | -0.16% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -19.25% |
| Revenue Per Employee | 288.73K |
| Profits Per Employee | -265.20K |
| Employee Count | 143 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.39 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -11.81% in the last 52 weeks. The beta is 1.16, so MaxCyte 's price volatility has been higher than the market average.
| Beta | 1.16 |
| 52-Week Price Change | -11.81% |
| 50-Day Moving Average | 3.91 |
| 200-Day Moving Average | 4.11 |
| Relative Strength Index (RSI) | 61.03 |
| Average Volume (20 Days) | 565.88K |
Income Statement
In the last 12 months, MaxCyte had revenue of 41.29M and earned -37.92M in profits. Earnings per share was -0.37.
| Revenue | 41.29M |
| Gross Profit | 36.55M |
| Operating Income | -48.30M |
| Net Income | -37.92M |
| EBITDA | -44.13M |
| EBIT | -48.30M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 46.51M in cash and 18.74M in debt, giving a net cash position of 27.76M.
| Cash & Cash Equivalents | 46.51M |
| Total Debt | 18.74M |
| Net Cash | 27.76M |
| Retained Earnings | -175.80M |
| Total Assets | 248.61M |
| Working Capital | 155.29M |
Cash Flow
In the last 12 months, operating cash flow was -21.69M and capital expenditures -3.70M, giving a free cash flow of -25.39M.
| Operating Cash Flow | -21.69M |
| Capital Expenditures | -3.70M |
| Free Cash Flow | -25.39M |
| FCF Per Share | -0.25 |
Margins
Gross margin is 88.51%, with operating and profit margins of -116.98% and -91.85%.
| Gross Margin | 88.51% |
| Operating Margin | -116.98% |
| Pretax Margin | -91.85% |
| Profit Margin | -91.85% |
| EBITDA Margin | -106.88% |
| EBIT Margin | -116.98% |
| FCF Margin | -61.49% |
Dividends & Yields
MXCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.99% |
| FCF Yield | -5.2% |
Analyst Forecast
The average price target for MXCT is $9.5, which is 105.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 105.2% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 6.86 |
| Piotroski F-Score | 2 |